

# Vladimir Cláudio Cordeiro de Lima

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9074630/publications.pdf>

Version: 2024-02-01

95  
papers

1,767  
citations

394390

19  
h-index

302107

39  
g-index

95  
all docs

95  
docs citations

95  
times ranked

2821  
citing authors

#	ARTICLE	IF	CITATIONS
1	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet, The</i> , 2017, 390, 555-566.	13.7	444
2	The neutrophil-to-lymphocyte ratio: a narrative review. <i>Ecancermedicalsecience</i> , 2016, 10, 702.	1.1	202
3	HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 155-163.	2.5	82
4	Lung cancer in Brazil. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 55-64.	0.7	71
5	B Cell Orchestration of Anti-tumor Immune Responses: A Matter of Cell Localization and Communication. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 678127.	3.7	63
6	NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer. <i>Journal of Biomedical Science</i> , 2021, 28, 26.	7.0	62
7	PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC). <i>Journal of Clinical Pathology</i> , 2021, 74, 735-740.	2.0	54
8	ADAM23 Negatively Modulates $\alpha v \beta 3$ Integrin Activation during Metastasis. <i>Cancer Research</i> , 2009, 69, 5546-5552.	0.9	50
9	EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP). <i>Lung Cancer</i> , 2018, 125, 265-272.	2.0	49
10	Lung Cancer in Brazil. <i>Journal of Thoracic Oncology</i> , 2020, 15, 170-175.	1.1	48
11	Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PivOTAL study. <i>European Journal of Cancer Care</i> , 2017, 26, e12734.	1.5	39
12	BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 803-814.	2.5	36
13	The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115). <i>Breast Cancer Research and Treatment</i> , 2020, 183, 749-757.	2.5	31
14	Acute bacterial infection negatively impacts cancer specific survival of colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 13930.	3.3	28
15	Immunotherapy as Single Treatment for Patients With NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis – the META-L-BRAIN Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1379-1391.	1.1	27
16	Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab. <i>International Journal of Clinical Oncology</i> , 2015, 20, 282-289.	2.2	26
17	Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival. <i>BMC Cancer</i> , 2015, 15, 643.	2.6	23
18	Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP). <i>Frontiers in Oncology</i> , 2019, 9, 254.	2.8	21

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1495-1503.	1.3	20
20	Advanced Stage at Diagnosis and Worse Clinicopathologic Features in Young Women with Breast Cancer in Brazil: A Subanalysis of the AMAZONA III Study (GBECAM 0115). <i>Journal of Global Oncology</i> , 2019, 5, 1-10.	0.5	20
21	A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma. <i>BMC Cancer</i> , 2021, 21, 901.	2.6	20
22	Inherited lung cancer: a review. <i>Ecancermedalscience</i> , 2020, 14, 1008.	1.1	20
23	Hyperglycemia increases the complicated infection and mortality rates during induction therapy in adult acute leukemia patients. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2013, 35, 39-43.	0.7	20
24	Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 782852.	4.8	19
25	Loss of prion protein is associated with the development of insulin resistance and obesity. <i>Biochemical Journal</i> , 2017, 474, 2981-2991.	3.7	18
26	Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Thoracic Cancer</i> , 2021, 12, 1058-1066.	1.9	18
27	Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103033.	4.4	17
28	Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients ( GBOT 0118/ ) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.9	17
29	The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma. <i>Medical Oncology</i> , 2019, 36, 8.	2.5	16
30	High Prevalence of EGFR Mutations in Lung Adenocarcinomas From Brazilian Patients Harboring the TP53 p.R337H Variant. <i>Clinical Lung Cancer</i> , 2020, 21, e37-e44.	2.6	16
31	Lung Cancer and the COVID-19 pandemic: Recommendations from the Brazilian Thoracic Oncology Group. <i>Clinics</i> , 2020, 75, e2060.	1.5	16
32	Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy. <i>Lasers in Medical Science</i> , 2017, 32, 1089-1095.	2.1	11
33	Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic. <i>Frontiers in Oncology</i> , 2020, 10, 1068.	2.8	11
34	Predictors of peritoneal carcinomatosis in patients with gastric cancer treated at a single institution in Brazil. <i>Journal of Surgical Oncology</i> , 2009, 100, 452-455.	1.7	10
35	Variants in Epithelial-Mesenchymal Transition and Immune Checkpoint Genes Are Associated With Immune Cell Profiles and Predict Survival in Non-Small Cell Lung Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1234-1244.	2.5	10
36	Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e511-e515.	2.6	10

#	ARTICLE	IF	CITATIONS
37	Primary Hodgkin's Lymphoma of the Rectum: An Unusual Presentation. <i>Journal of Clinical Oncology</i> , 2011, 29, e268-e270.	1.6	8
38	TNF-alpha and melphalan modulate a specific group of early expressed genes in a murine melanoma model. <i>Cytokine</i> , 2013, 62, 217-225.	3.2	8
39	Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP). <i>Thoracic Cancer</i> , 2019, 10, 508-518.	1.9	8
40	Volatile organic compounds analysis optimization and biomarker discovery in urine of Non-Hodgkin lymphoma patients before and during chemotherapy. <i>Microchemical Journal</i> , 2020, 159, 105479.	4.5	8
41	Malignant pleural mesothelioma: an update. <i>Jornal Brasileiro De Pneumologia</i> , 2021, 47, e20210129.	0.7	8
42	NDRG4 promoter hypermethylation is a mechanistic biomarker associated with metastatic progression in breast cancer patients. <i>Npj Breast Cancer</i> , 2019, 5, 11.	5.2	7
43	Gas chromatography-mass spectrometry untargeted profiling of non-Hodgkin's lymphoma urinary metabolite markers. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 7469-7480.	3.7	7
44	Factors correlated with peritoneal carcinomatosis and survival in patients with gastric cancer treated at a single institution in Brazil. <i>International Journal of Clinical Oncology</i> , 2009, 14, 326-331.	2.2	6
45	Pulmonary Neuroendocrine Neoplasms Overexpressing Epithelial-Mesenchymal Transition Mechanical Barriers Genes Lack Immune-Suppressive Response and Present an Increased Risk of Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 645623.	2.8	6
46	Paradoxical interaction between cancer and long-term postsepsis disorder: impairment of de novo carcinogenesis versus favoring the growth of established tumors. , 2020, 8, e000129.		5
47	Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma. <i>BMC Cancer</i> , 2021, 21, 209.	2.6	5
48	Mutational Signatures Driven by Epigenetic Determinants Enable the Stratification of Patients with Gastric Cancer for Therapeutic Intervention. <i>Cancers</i> , 2021, 13, 490.	3.7	5
49	Association of hypothyroidism with improved outcomes in first-line treatment of renal cell carcinoma with sunitinib.. <i>Journal of Clinical Oncology</i> , 2012, 30, 466-466.	1.6	4
50	An integrative microenvironment approach for follicular lymphoma: roles of inflammatory cell subsets and immune-response polymorphisms on disease clinical course. <i>Oncotarget</i> , 2020, 11, 3153-3173.	1.8	4
51	Palatal ulcerations and midfacial swelling. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2009, 108, 483-487.	1.4	3
52	Stage III Non-Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort. <i>Journal of Global Oncology</i> , 2018, 4, 1-11.	0.5	3
53	Single-nucleotide variants in TGFBI, TGFBR2, IL17A, and IL17F immune response genes contribute to follicular lymphoma susceptibility and aggressiveness. <i>Blood Cancer Journal</i> , 2020, 10, 97.	6.2	3
54	Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP-LATImus). <i>Thoracic Cancer</i> , 2021, 12, 1328-1335.	1.9	3

#	ARTICLE	IF	CITATIONS
55	Breast cancer patients have increased risk of developing mTOR inhibitor-associated stomatitis. Oral Diseases, 2018, 24, 207-209.	3.0	2
56	A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases. Journal of Thoracic Disease, 2019, 11, 3909-3919.	1.4	2
57	EP1.04-45 Relevance of Antibiotic Use on Clinical Activity of Immune Checkpoint Inhibitors in Hispanic Patients with Advanced NSCLC (CLICAP-ABs). Journal of Thoracic Oncology, 2019, 14, S972.	1.1	2
58	BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas. Leukemia Research, 2021, 110, 106689.	0.8	2
59	Total tumor burden as predictive tool of response and survival of patients with metastatic melanoma treated with nivolumab.. Journal of Clinical Oncology, 2017, 35, e21022-e21022.	1.6	2
60	Lower prevalence of PD-L1 expression in advanced non-small lung cancer in Brazil.. Journal of Clinical Oncology, 2018, 36, e21140-e21140.	1.6	2
61	Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals. Hematology, Transfusion and Cell Therapy, 2018, 40, 343-353.	0.2	1
62	PD1.05 Relevance of Antibiotic Use on Clinical Activity of Immune Checkpoint Inhibitors in Hispanic Patients with Advanced Non-small-cell Lung Cancer (CLICAP-ABs). Journal of Thoracic Oncology, 2019, 14, S1168.	1.1	1
63	P1.14-61 EGFR Inhibitors Plus Bevacizumab Are Superior Compared to EGFR Inhibitor Monotherapy in Advanced EGFR+ NSCLC Patients with BIM Deletions. Journal of Thoracic Oncology, 2019, 14, S579.	1.1	1
64	P1.04-76 Predictive Factors of Early Therapeutic Failure to Immunotherapy in Patients with Metastatic NSCLC. Journal of Thoracic Oncology, 2019, 14, S472.	1.1	1
65	256P Risk of CNS metastasis after neoadjuvant chemotherapy: Pathological complete response may not be enough. Annals of Oncology, 2020, 31, S342.	1.2	1
66	Abstract P6-09-44: Tumor-infiltrating lymphocytes (TILs) is associated with improved overall survival in triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy (NAC)., 2017, , .		1
67	PTEN and cetuximab resistance in head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2017, 35, 6061-6061.	1.6	1
68	Abstract P1-08-27: Advanced stage at diagnosis and worse clinicopathologic features in young woman with breast cancer. A sub-analysis of Brazilian population through the AMAZONA III study (GBECAM) Tj ETQqO O O rgBT /Overlock 10 TF 5		1
69	Abstract P5-01-19: Circulating tumor DNA (ctDNA) analysis for investigating resistance to chemotherapy with DNA-damage agents in patients with hereditary or sporadic triple-negative breast cancer. Cancer Research, 2020, 80, P5-01-19-P5-01-19.	0.9	1
70	P2.02-030 Consolidation Chemotherapy Following Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: A Brazilian Multicentric Cohort. Journal of Thoracic Oncology, 2017, 12, S865-S866.	1.1	0
71	P1.01-23 High PD-L1 Expression is Less Common Than Expected Among Advanced NSCLC in Brazil. Are We Missing the Target?. Journal of Thoracic Oncology, 2018, 13, S468-S469.	1.1	0
72	PD.1.06 EGFR Uncommon Mutations Frequency in a 1,688 NSCLC Patients Database in Brazil. Journal of Thoracic Oncology, 2018, 13, S157.	1.1	0

#	ARTICLE	IF	CITATIONS
73	EP1.04-44 Exploration of Factors Relating to Paradoxical Immune Response in Patients Treated with Immune Checkpoint Inhibitors for NSCLC. Journal of Thoracic Oncology, 2019, 14, S971.	1.1	0
74	PD2.03 Exploration of Factors Relating to Immune Response in Patients Treated with Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2019, 14, S1171.	1.1	0
75	P1.10 Survival of Thymoma Is Extensive in Latin-American Patients: Results from over 10 Years of Experience (CLICaP-LATimus). Journal of Thoracic Oncology, 2019, 14, S1177-S1178.	1.1	0
76	P1.12 Real World Characterization and Treatment Patterns of Patients with Thymic Carcinoma: Lessons from a Latin American Collaborative Study (CLICaP-LATimus). Journal of Thoracic Oncology, 2019, 14, S1178-S1179.	1.1	0
77	PD2.06 EGFR Inhibitors + Bevacizumab Demonstrated Superior Efficacy Compared with EGFR Inhibitors Alone as First-line Treatment in Advanced NSCLC Patients with EGFR Mutations and BIM Deletion Polymorphisms. Journal of Thoracic Oncology, 2019, 14, S1172-S1173.	1.1	0
78	P2.11-28 Late-Breaking Abstract - Clinical Potential of Sputum Hyaluronan Measurement in the Diagnosis and Prognosis of Patients with NSCLC. Journal of Thoracic Oncology, 2019, 14, S803-S804.	1.1	0
79	P2.11-12 Sputum Liquid Biopsy Provides a Non-Invasive Modality to Assess Driver Mutations and Tumor Heterogeneity in NSCLC. Journal of Thoracic Oncology, 2019, 14, S796-S797.	1.1	0
80	P1.09-02 Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer in Brazil (GBOT 0118/LACOG) Tj ETQq0 0,0 rgBT /Qverlock 10	1.1	0
81	P1.11-38 Frequency and Prognostic Impact of Concomitant Mutations in KRAS and TP53 or STK11 in Brazilian Lung Adenocarcinoma Patients. Journal of Thoracic Oncology, 2019, 14, S532.	1.1	0
82	P1.04-80 Immunotherapy-Related Thrombosis: Considerations and Associated Factors in Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology, 2019, 14, S473-S474.	1.1	0
83	P2.22 Immunotherapy-related Thrombosis: Considerations and Associated Factors in Non-small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology, 2019, 14, S1194.	1.1	0
84	406P Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis. Annals of Oncology, 2020, 31, S1401.	1.2	0
85	BUCYE can Safely Replace BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation for Relapsed Lymphomas. Biology of Blood and Marrow Transplantation, 2020, 26, S152.	2.0	0
86	Genetic Ancestry Affects Somatic Alterations in Lung Cancers. Cancer Discovery, 2021, 11, 1320-1321.	9.4	0
87	Retrospective comparison between conventional-dose chemotherapy and high-dose chemotherapy for the treatment of relapsed or metastatic germ cell tumors.. Journal of Clinical Oncology, 2010, 28, e15105-e15105.	1.6	0
88	Comparison of pemetrexed plus cisplatin versus pemetrexed plus carboplatin in the initial treatment of locally advanced or metastatic non-small cell lung cancer.. Journal of Clinical Oncology, 2011, 29, e18067-e18067.	1.6	0
89	Impact of oral mucositis on outcomes of multiple myeloma patients treated with high-dose melphalan conditioning and autologous stem cell transplantation (ASCT).. Journal of Clinical Oncology, 2013, 31, 7037-7037.	1.6	0
90	EGFRv3 and PTEN as prognostic markers in head and neck squamous cell carcinoma patients treated with cetuximab.. Journal of Clinical Oncology, 2013, 31, e17032-e17032.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Cisplatin, gemcitabine, and vinorelbine (PGV) compared with cisplatin and etoposide (PE) in the first-line treatment of extensive-stage small-cell lung cancer: Two Brazilian institution experience.. Journal of Clinical Oncology, 2013, 31, e18548-e18548.	1.6	0
92	Evaluation of lymphocyte infiltrate composition in triple-negative mammary carcinomas and its association with clinical-pathologic and demographic data.. Journal of Clinical Oncology, 2014, 32, 1131-1131.	1.6	0
93	Abstract 4908: Exemestane worsens everolimus-associated stomatitis in cancer patients. , 2018, , .		0
94	A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases.. Journal of Clinical Oncology, 2019, 37, e20604-e20604.	1.6	0
95	Abstract 2213: Investigation of treatment resistance with DNA-damage agents in patients with triple negative breast cancer by ctDNA. , 2019, , .		0